Proprietary Products — R&D
West Pharmaceutical Services Proprietary Products — R&D decreased by 27.5% to $15.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.1%, from $16.30M to $15.80M. Over 3 years (FY 2022 to FY 2025), Proprietary Products — R&D shows an upward trend with a 8.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher investment suggests a focus on long-term innovation and market leadership, while significant cuts may signal a shift toward short-term profitability.
Detailed definition
This represents the expenses incurred by the proprietary products segment to develop new technologies, improve existing...
Peer comparison
Comparable to R&D spending in medical technology and pharmaceutical supply companies.
wst_segment_proprietary_products_research_and_developmentHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.63M | $14.63M | $14.63M | $14.63M | $17.10M | $17.10M | $17.10M | $17.10M | $17.60M | $17.50M | $15.50M | $18.50M | $16.30M | $19.10M | $17.10M | $21.80M | $15.80M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +16.9% | +0.0% | +0.0% | +0.0% | +2.9% | -0.6% | -11.4% | +19.4% | -11.9% | +17.2% | -10.5% | +27.5% | -27.5% |
| YoY Change | — | — | — | — | +16.9% | +16.9% | +16.9% | +16.9% | +2.9% | +2.3% | -9.4% | +8.2% | -7.4% | +9.1% | +10.3% | +17.8% | -3.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's proprietary products — r&d?
- West Pharmaceutical Services (WST) reported proprietary products — r&d of $15.80M in Q1 2026.
- How has West Pharmaceutical Services's proprietary products — r&d changed year-over-year?
- West Pharmaceutical Services's proprietary products — r&d decreased by 3.1% year-over-year, from $16.30M to $15.80M.
- What is the long-term trend for West Pharmaceutical Services's proprietary products — r&d?
- Over 3 years (2022 to 2025), West Pharmaceutical Services's proprietary products — r&d has grown at a 8.3% compound annual growth rate (CAGR), from $58.50M to $74.30M.
- What does proprietary products — r&d mean?
- Spending on innovation and the development of new or improved products.